Illumina falls on Q3 revenue miss

** Gene sequencing company Illumina ILMN.O shares fall 13.5% to $251

** Co late on Thursday reported Q3 revenue of $1.13 billion, missing estimates of $1.15 billion, as per LSEG data

** Revenue excluding tariff refunds was $1.17 billion

** Q3 EPS of $1.44 per share beats analyst estimates of $1.36 per share

** "Q3 was fine. The stock wasn't priced for "fine - we could see near-term pressure" - UBS analysts

** Co said customer demand for its DNA sequencing platform, NovaSeq X, remains at very high levels with co placing over 80 instruments orders during the quarter

** "While NovaSeq X placements remain elevated at >80, the lack of flow through to instrument revenues is an issue, as is further q/q deceleration in clinical consumables" - Jefferies analysts

** We anticipate shares to be pressured given typical Sequencing results that were lower than consensus, further muddied by tariff impacts, Citi analysts said

** Including session moves, tock up 90.2% YTD